605 related articles for article (PubMed ID: 7760868)
1. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B.
Stone RM; Berg DT; George SL; Dodge RK; Paciucci PA; Schulman P; Lee EJ; Moore JO; Powell BL; Schiffer CA
N Engl J Med; 1995 Jun; 332(25):1671-7. PubMed ID: 7760868
[TBL] [Abstract][Full Text] [Related]
2. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group.
Dombret H; Chastang C; Fenaux P; Reiffers J; Bordessoule D; Bouabdallah R; Mandelli F; Ferrant A; Auzanneau G; Tilly H
N Engl J Med; 1995 Jun; 332(25):1678-83. PubMed ID: 7539109
[TBL] [Abstract][Full Text] [Related]
3. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B.
Mayer RJ; Davis RB; Schiffer CA; Berg DT; Powell BL; Schulman P; Omura GA; Moore JO; McIntyre OR; Frei E
N Engl J Med; 1994 Oct; 331(14):896-903. PubMed ID: 8078551
[TBL] [Abstract][Full Text] [Related]
4. Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia.
Pui CH; Boyett JM; Hughes WT; Rivera GK; Hancock ML; Sandlund JT; Synold T; Relling MV; Ribeiro RC; Crist WM; Evans WE
N Engl J Med; 1997 Jun; 336(25):1781-7. PubMed ID: 9187068
[TBL] [Abstract][Full Text] [Related]
5. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia.
Löwenberg B; van Putten W; Theobald M; Gmür J; Verdonck L; Sonneveld P; Fey M; Schouten H; de Greef G; Ferrant A; Kovacsovics T; Gratwohl A; Daenen S; Huijgens P; Boogaerts M; ;
N Engl J Med; 2003 Aug; 349(8):743-52. PubMed ID: 12930926
[TBL] [Abstract][Full Text] [Related]
6. Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia.
Ohno R; Tomonaga M; Kobayashi T; Kanamaru A; Shirakawa S; Masaoka T; Omine M; Oh H; Nomura T; Sakai Y
N Engl J Med; 1990 Sep; 323(13):871-7. PubMed ID: 1697646
[TBL] [Abstract][Full Text] [Related]
7. Neutrophil recovery time and adverse side effects in acute leukemia patients treated with intensive chemotherapy and concomitant G or GM-CSF.
Alvarado Ibarra ML; Borbolla Escoboza JR; López-Hernández MA; González-Avante CM; FloresChapa JD; Trueba Christy E; Anaya Cuellar I
Rev Invest Clin; 1999; 51(2):77-80. PubMed ID: 10410585
[TBL] [Abstract][Full Text] [Related]
8. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
9. A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM).
Witz F; Sadoun A; Perrin MC; Berthou C; Brière J; Cahn JY; Lioure B; Witz B; François S; Desablens B; Pignon B; Le Prisé PY; Audhuy B; Caillot D; Casassus P; Delain M; Christian B; Tellier Z; Polin V; Hurteloup P; Harousseau JL
Blood; 1998 Apr; 91(8):2722-30. PubMed ID: 9531581
[TBL] [Abstract][Full Text] [Related]
10. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of subcutaneous recombinant human interleukin 11 with subcutaneous recombinant human granulocyte-macrophage colony stimulating factor in patients with acute myeloid leukemia (AML) receiving high-dose cytarabine during induction: ECOG 3997.
Cripe LD; Rader K; Tallman MS; Gordon MS; Paietta E; Bennett J; Neuberg D; Litzow MR; O'brien TE; Rowe JM
Leuk Res; 2006 Jul; 30(7):823-7. PubMed ID: 16413056
[TBL] [Abstract][Full Text] [Related]
12. High-dose cytarabine, idarubicin, and granulocyte colony-stimulating factor remission induction therapy for previously untreated de novo and secondary adult acute myeloid leukemia.
Baer MR; Christiansen NP; Frankel SR; Brunetto VL; Mrózek K; Bloomfield CD; Herzig GP
Semin Oncol; 1993 Dec; 20(6 Suppl 8):6-12. PubMed ID: 7507264
[TBL] [Abstract][Full Text] [Related]
13. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups.
Zittoun RA; Mandelli F; Willemze R; de Witte T; Labar B; Resegotti L; Leoni F; Damasio E; Visani G; Papa G
N Engl J Med; 1995 Jan; 332(4):217-23. PubMed ID: 7808487
[TBL] [Abstract][Full Text] [Related]
14. Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group.
Zittoun R; Suciu S; Mandelli F; de Witte T; Thaler J; Stryckmans P; Hayat M; Peetermans M; Cadiou M; Solbu G; Petti MC; Willemze R
J Clin Oncol; 1996 Jul; 14(7):2150-9. PubMed ID: 8683249
[TBL] [Abstract][Full Text] [Related]
15. GM-CSF accelerates neutrophil recovery after autologous hematopoietic stem cell transplantation.
Greenberg P; Advani R; Keating A; Gulati SC; Nimer S; Champlin R; Karanes C; Gorin NC; Powles RL; Smith A; Lamborn K; Cuffie C
Bone Marrow Transplant; 1996 Dec; 18(6):1057-64. PubMed ID: 8971373
[TBL] [Abstract][Full Text] [Related]
16. GM-CSF in a double-blind randomized, placebo controlled trial in therapy of adult patients with de novo acute myeloid leukemia (AML).
Heil G; Chadid L; Hoelzer D; Seipelt G; Mitrou P; Huber C; Kolbe K; Mertelsmann R; Lindemann A; Frisch J
Leukemia; 1995 Jan; 9(1):3-9. PubMed ID: 7845026
[TBL] [Abstract][Full Text] [Related]
17. A double-blind placebo-controlled study with granulocyte-macrophage colony-stimulating factor during chemotherapy for ovarian carcinoma.
de Vries EG; Biesma B; Willemse PH; Mulder NH; Stern AC; Aalders JG; Vellenga E
Cancer Res; 1991 Jan; 51(1):116-22. PubMed ID: 1988077
[TBL] [Abstract][Full Text] [Related]
18. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
Wong SF; Chan HO
Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
[TBL] [Abstract][Full Text] [Related]
19. Granulocyte-macrophage colony-stimulating factor in association to timed-sequential chemotherapy with mitoxantrone, etoposide, and cytarabine for refractory acute myelogenous leukemia.
Archimbaud E; Fenaux P; Reiffers J; Cordonnier C; Leblond V; Travade P; Troussard X; Tilly H; Auzanneau G; Marie JP
Leukemia; 1993 Mar; 7(3):372-7. PubMed ID: 8445942
[TBL] [Abstract][Full Text] [Related]
20. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim.
Weaver CH; Schulman KA; Buckner CD
Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
